Search Clinical Trials
589,087 trials
ID
Status
Phase
Title
Sponsor
NCT07644208
PD-1/IL-2 Bispecific Antibody as Neoadjuvant Therapy for Early Recurrent Hepatocellular Carcinoma After Curative HepatectomyShanghai Zhongshan HospitalNot Yet RecruitingPhase 2
NCT07644208Not Yet Recruiting
Phase 2
PD-1/IL-2 Bispecific Antibody as Neoadjuvant Therapy for Early Recurrent Hepatoc...Shanghai Zhongshan Hospit...
NCT07645924
A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of MigraineKallyope Inc.Not Yet RecruitingPhase 3
NCT07645924Not Yet Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute T...Kallyope Inc.
NCT07645846
Neoadjuvant Docetaxel, Cisplatin, and Dual Immunotherapy for Sinonasal CarcinomaFirst Affiliated Hospital, Sun Yat-Sen UniversityNot Yet RecruitingPhase 2
NCT07645846Not Yet Recruiting
Phase 2
Neoadjuvant Docetaxel, Cisplatin, and Dual Immunotherapy for Sinonasal CarcinomaFirst Affiliated Hospital...
NCT07643792
Fascia Iliaca Block Using Liposomal Bupivacaine for Analgesia After Hip Fracture SurgeryPeking University First HospitalNot Yet RecruitingPhase 4
NCT07643792Not Yet Recruiting
Phase 4
Fascia Iliaca Block Using Liposomal Bupivacaine for Analgesia After Hip Fracture...Peking University First H...
NCT07644390
Development of a Dynamic Prediction Model for Crohn's Disease-Related Intestinal Surgery Using Longitudinal Indices of Routine Blood Tests: A Single-Center Retrospective Cohort StudySixth Affiliated Hospital, Sun Yat-sen UniversityCompleted
NCT07644390Completed
—
Development of a Dynamic Prediction Model for Crohn's Disease-Related Intestinal...Sixth Affiliated Hospital...
NCT07644650
Phase 1 Study of MST-168 in Participants With Advanced Solid Malignant TumorsMabsoft Therapeutics (Australia) Pty. Ltd.Not Yet RecruitingPhase 1
NCT07644650Not Yet Recruiting
Phase 1
Phase 1 Study of MST-168 in Participants With Advanced Solid Malignant TumorsMabsoft Therapeutics (Aus...
NCT07645638
Virtual Reality Cognitive Stimulation for Alzheimer'sUniversidad de BurgosCompletedNot Applicable
NCT07645638Completed
Not Applicable
Virtual Reality Cognitive Stimulation for Alzheimer'sUniversidad de Burgos
NCT07645690
The Safety and Efficacy of Allogeneic CD70 CAR-T Therapy in Unresectable or Metastatic Clear Cell Renal Cell CarcinomaChinese PLA General HospitalRecruitingEarly Phase 1
NCT07645690Recruiting
Early Phase 1
The Safety and Efficacy of Allogeneic CD70 CAR-T Therapy in Unresectable or Meta...Chinese PLA General Hospi...
NCT07645443
FEEL-GOOD: A Multicenter Trial of a Mindfulness-Based Group Therapy in Young Adults With Early PsychosisCentral Institute of Mental Health, MannheimRecruitingNot Applicable
NCT07645443Recruiting
Not Applicable
FEEL-GOOD: A Multicenter Trial of a Mindfulness-Based Group Therapy in Young Adu...Central Institute of Ment...
NCT07645430
Assessment of Interleukin-15 and Interferon Gamma in Alopecia Areata Before and After Baricitinib.Benha UniversityCompletedNot Applicable
NCT07645430Completed
Not Applicable
Assessment of Interleukin-15 and Interferon Gamma in Alopecia Areata Before and...Benha University
NCT07644936
Molecular Characterization of Autoimmune Hepatitis: A Lipidomic ApproachAzienda Ospedaliera Specializzata in Gastroenterologia Saverio de BellisNot Yet Recruiting
NCT07644936Not Yet Recruiting
—
Molecular Characterization of Autoimmune Hepatitis: A Lipidomic ApproachAzienda Ospedaliera Speci...
NCT07645586
A Phase 3 Trial of Lesion Network Mapping-Guided cTBS for Motor Recovery After Acute Ischemic StrokeBeijing Tiantan HospitalNot Yet RecruitingPhase 3
NCT07645586Not Yet Recruiting
Phase 3
A Phase 3 Trial of Lesion Network Mapping-Guided cTBS for Motor Recovery After A...Beijing Tiantan Hospital
NCT07646145
Disitamab Vedotin Plus Intravesical Mitomycin C in HER2-Expressing Intermediate- to High-Risk Non-Muscle-Invasive Bladder CancerShanxi Province Cancer HospitalRecruitingPhase 2
NCT07646145Recruiting
Phase 2
Disitamab Vedotin Plus Intravesical Mitomycin C in HER2-Expressing Intermediate-...Shanxi Province Cancer Ho...
NCT07645274
Improving Mental Healthcare Outcomes for Minoritized Veterans Through a Peer-led, Patient Navigation Program (PARTNER-MH 2.0)Indiana UniversityNot Yet RecruitingNot Applicable
NCT07645274Not Yet Recruiting
Not Applicable
Improving Mental Healthcare Outcomes for Minoritized Veterans Through a Peer-led...Indiana University
NCT07645339
Efficacy and Safety of a Topical Botanical Extract Formulation for Skin Barrier RepairL'OrealActive Not RecruitingNot Applicable
NCT07645339Active Not Recruiting
Not Applicable
Efficacy and Safety of a Topical Botanical Extract Formulation for Skin Barrier...L'Oreal
NCT07644897
Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients With Advanced MelanomaSun Yat-sen UniversityRecruitingPhase 2
NCT07644897Recruiting
Phase 2
Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients...Sun Yat-sen University
NCT07644494
Distensibility Index of Inferior Vena Cava in Assessing Fluid Responsiveness: The Impact of Spontaneous Respiratory EffortJingyuan,XuCompleted
NCT07644494Completed
—
Distensibility Index of Inferior Vena Cava in Assessing Fluid Responsiveness: Th...Jingyuan,Xu
NCT07644169
A Clinical Trial to Assess the Pharmacokinetic Profile of Propylene Glycol (PG) in Healthy Adults Following PG ExposureAmerican Beverage AssociationNot Yet RecruitingNot Applicable
NCT07644169Not Yet Recruiting
Not Applicable
A Clinical Trial to Assess the Pharmacokinetic Profile of Propylene Glycol (PG)...American Beverage Associa...
NCT07644195
Study to Evaluate Safety and Activity of Inhaled TRL1068 in Healthy VolunteersNational Institute of Allergy and Infectious Diseases (NIAID)Not Yet RecruitingPhase 1
NCT07644195Not Yet Recruiting
Phase 1
Study to Evaluate Safety and Activity of Inhaled TRL1068 in Healthy VolunteersNational Institute of All...
Result Breakdown
Not yet recruiting11 (55%)
Completed4 (20%)
Recruiting4 (20%)
Active, not recruiting1 (5%)
not_applicable6 (30%)
Phase 24 (20%)
Not Specified4 (20%)
Phase 32 (10%)
Phase 12 (10%)
Phase 41 (5%)
Early Phase 11 (5%)